Stocks › Biotechnology › CRMD

CorMedix CRMD

US equityMarket cap rank #3658Biotechnology

$7.28 +$0.00 (0.00%)

Pre-market · Oct 8, 8:20 am ET · After hours $7.30 +0.28%

Open$7.27

Prev close$7.28

Day range$7.18 – $7.31

Volume833.1K

Market cap$567.43M

P/E (TTM)3.3

Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership57.0%-0.75 pts vs. prior quarter

Institutions holding222-2 vs. prior quarter

Insider trades (recent)21 buys / 29 sellsNet selling

Short interest20.79% of floatDays to cover 18.5 · as of 15 Sep 2026

Short-sale volume share27.6%5-day average of daily volume

Short-sale volume as % of daily volume

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$89.0K (12 inflow days, 8 outflow days).

Net flow by order size, last 20 sessions

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 29.7% of shares outstanding.

Largest holders

BlackRock8.11%
Deep Track Capital, LP8.05%
Shaibatalhamd Abdalkader5.93%
Vanguard Capital Management, LLC4.64%
State Street Global Advisors2.97%
Royce & Associates, LP2.79%
UBS Asset Management2.56%
Geode Capital Management, LLC2.50%

By investor type

Mutual Fund39.08%
VC/PE Fund8.05%
Individual/Insider7.42%
Hedge Fund5.27%
Public Company1.97%
Private Company1.59%
Government Pension Fund0.69%
Insurance Company0.25%

Reported short interest has risen from 19.03% to 20.79% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

Holder	Type	Period	Share change	New stake
Nuveen Asset Management LLC	Insurance Company	2026/Q3	+173,182	0.2%
Bridgeway Capital Management, LLC	Mutual Fund	2026/Q3	+551,664	0.9%
Armistice Capital LLC	Hedge Fund	2026/Q3	+500,000	0.6%
BlackRock	Mutual Fund	2026/Q3	+356,536	8.1%
Hudson River Trading LLC	Private Company	2026/Q3	+333,113	0.8%
American Century Investment Management	Mutual Fund	2026/Q3	+318,939	0.4%
Royce & Associates, LP	Mutual Fund	2026/Q3	+288,830	2.8%
UBS Asset Management	Mutual Fund	2026/Q3	+281,553	2.6%
Marshall Wace LLP	Hedge Fund	2026/Q3	+276,570	1.0%
Hennion & Walsh Asset Management, Inc.	Mutual Fund	2026/Q3	+263,618	0.6%
Balyasny Asset Management L.P.	Hedge Fund	2026/Q3	+202,370	0.3%
Leap Investments LP	Mutual Fund	2026/Q3	+180,000	0.2%
D. E. Shaw & Co., L.P.	Hedge Fund	2026/Q3	+171,807	0.2%
Susquehanna International Group, LLP	Private Company	2026/Q3	+155,113	0.4%
Jane Street Group, LLC	Private Company	2026/Q3	+145,146	0.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

Date	Insider	Title	Transaction	Shares	Price	Held after
17 Sep 2026	Janet Dillione	Independent Director	Derivative Exercise and Retained	+48,909	–	87,382
28 Aug 2026	Elizabeth Masson-Hurlburt	Executive VP and Head of Clinical & Medical Affairs	Sale to Issuer	-8,076	$8.30	86,106
28 Aug 2026	Susan Blum	EVP & Chief Financial Officer	Sale to Issuer	-8,424	$8.30	17,436
28 Aug 2026	Kaufman Zelnick	Executive Vice President	Sale to Issuer	-8,424	$8.30	101,313
3 Feb 2026	Joseph Todisco	Chief Executive Officer	Other Acquisition	+77,156	–	373,664
3 Feb 2026	Elizabeth Masson-Hurlburt	Executive VP and Head of Clinical & Medical Affairs	Other Acquisition	+36,006	–	214,278
3 Feb 2026	Kaufman Zelnick	Executive Vice President	Other Acquisition	+36,006	–	–
25 Jan 2026	Myron Kaplan	Independent Chairperson	Other Acquisition	+30,453	–	30,453
25 Jan 2026	Alan Dunton	Independent Director	Other Acquisition	+30,453	–	30,453
25 Jan 2026	Janet Dillione	Independent Director	Other Acquisition	+30,453	–	30,453
25 Jan 2026	Steven Lefkowitz	Independent Director	Other Acquisition	+30,453	–	30,453
25 Jan 2026	Robert Stewart	Independent Director	Other Acquisition	+30,453	–	30,453
25 Jan 2026	Gregory Duncan	Independent Director	Other Acquisition	+30,453	–	30,453
22 Jan 2026	Joseph Todisco	Chief Executive Officer	Sale to Issuer	-27,306	$7.27	344,610
22 Jan 2026	Joseph Todisco	Chief Executive Officer	Other Acquisition	+225,900	–	352,983
22 Jan 2026	Elizabeth Masson-Hurlburt	Executive VP and Head of Clinical & Medical Affairs	Sale to Issuer	-10,778	$7.27	76,761
22 Jan 2026	Elizabeth Masson-Hurlburt	Executive VP and Head of Clinical & Medical Affairs	Other Acquisition	+93,010	–	165,772
22 Jan 2026	Susan Blum	EVP & Chief Financial Officer	Sale to Issuer	-9,767	$7.27	8,438
22 Jan 2026	Susan Blum	EVP & Chief Financial Officer	Other Acquisition	+72,820	–	124,301
22 Jan 2026	Kaufman Zelnick	Executive Vice President	Sale to Issuer	-8,803	$7.27	–

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report date	Shares short	% of float	Days to cover
15 Sep 2026	16,202,272	20.8%	18.5
31 Aug 2026	16,032,112	20.6%	13.0
14 Aug 2026	17,149,908	22.0%	11.1
31 Jul 2026	16,283,087	20.8%	17.1
15 Jul 2026	15,349,811	19.6%	17.0
30 Jun 2026	14,930,822	19.0%	7.8

Discussion

No comments yet — be the first to weigh in on CRMD.